JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB208076

Alexa Fluor® 555 Anti-MEK1 + MEK2 antibody [EPR16667]

Be the first to review this product! Submit a review

|

(1 Publication)

Rabbit Recombinant Monoclonal MEK1 antibody - conjugated to Alexa Fluor® 555. Suitable for ICC/IF and reacts with Human samples. Cited in 1 publication.

View Alternative Names

MEK1, PRKMK1, MAP2K1, Dual specificity mitogen-activated protein kinase kinase 1, MAP kinase kinase 1, MAPKK 1, MKK1, ERK activator kinase 1, MAPK/ERK kinase 1, MEK 1

1 Images
Immunocytochemistry/ Immunofluorescence - Alexa Fluor® 555 Anti-MEK1 + MEK2 antibody [EPR16667] (AB208076)
  • ICC/IF

Lab

Immunocytochemistry/ Immunofluorescence - Alexa Fluor® 555 Anti-MEK1 + MEK2 antibody [EPR16667] (AB208076)

ab208076 staining MEK1 + MEK2 in A431 cells. The cells were fixed with 100% methanol (5 min), permeabilized with 0.1% Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1% PBS-Tween for 1h. The cells were then incubated overnight at +4°C with ab208076 at a 1/50 dilution (pseudocolored in green) and ab195884, Rat monoclonal to alpha Tubulin (Alexa Fluor® 647), at a 1/250 dilution (shown in red). Nuclear DNA was labelled with DAPI (shown in blue).

Image was taken with a confocal microscope (Leica-Microsystems, TCS SP8).

This product also gave a positive signal under the same testing conditions in A431 cells fixed with 4% formaldehyde (10 min).

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-MEK1 + MEK2 antibody [EPR16667]

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-MEK1 + MEK2 antibody [EPR16667]

  • 660 APC

    APC Anti-MEK1 + MEK2 antibody [EPR16667]

  • 578 PE

    PE Anti-MEK1 + MEK2 antibody [EPR16667]

  • HRP

    HRP Anti-MEK1 + MEK2 antibody [EPR16667]

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR16667

Isotype

IgG

Conjugation

Alexa Fluor® 555

Excitation/Emission

Ex: 555nm, Em: 565nm

Carrier free

No

Reacts with

Human

Applications

ICC/IF

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/50", "ICCIF-species-notes": "<p>This product gave a positive signal in A431 cells fixed with 4% formaldehyde (10 min) and 100% methanol (5 min)</p>" }, "Mouse": { "ICCIF-species-checked": "predicted", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" }, "Rat": { "ICCIF-species-checked": "predicted", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" } } }

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle|Store in the dark

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

MEK1 and MEK2 also known as MAP2K1 and MAP2K2 respectively are dual-specificity kinases that play roles in signaling pathways mediating cellular responses. MEK1 and MEK2 have molecular weights of approximately 45kDa. They are expressed in various tissues including the heart brain and skeletal muscles reflecting their widespread function within the organism. These proteins are often referred collectively as the MEK1/2 complex due to their shared and overlapping roles in cell signaling.
Biological function summary

MEK1 and MEK2 are integral parts of the mitogen-activated protein kinase (MAPK) signaling cascade. MEK1/2 phosphorylate and activate the ERK1/2 kinases which transmit signals from the cell surface to the nucleus regulating gene expression and cell fate decisions. The MEK1/2 proteins also act in concert with other kinases and substrates forming signaling complexes that ensure specific and regulated cellular outcomes.

Pathways

MEK1 and MEK2 play key roles within the MAPK/ERK pathway a critical signaling mechanism for cell division and survival. They also link to the RAS/MAPK pathway involved in transmitting signals from membrane receptors to the nucleus. In these pathways MEK1/2 interact with proteins like RAF kinases and ERK1/2 propagating signals that influence cellular growth and differentiation.

MEK1 and MEK2 are implicated in cancer and neurological disorders. Abnormal activity of the MEK1/2 proteins often due to mutations can lead to uncontrolled cell proliferation contributing to the development of cancers such as melanoma. In neurological disorders dysregulation of MEK1/2 signaling relates to conditions like neuro-cardio-facial-cutaneous syndromes. These proteins interact with other key players in these diseases such as mutant RAF proteins in melanoma highlighting their critical roles in disease mechanisms.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leading to their activation and further transduction of the signal within the MAPK/ERK cascade. Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation (PubMed : 29433126). Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis.
See full target information MAP2K1

Additional targets

MAP2K2

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Nature communications 9:2024 PubMed29789628

2018

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models.

Applications

Unspecified application

Species

Unspecified reactive species

Samuel Y Ng,Noriaki Yoshida,Amanda L Christie,Mahmoud Ghandi,Neekesh V Dharia,Joshua Dempster,Mark Murakami,Kay Shigemori,Sara N Morrow,Alexandria Van Scoyk,Nicolas A Cordero,Kristen E Stevenson,Maneka Puligandla,Brian Haas,Christopher Lo,Robin Meyers,Galen Gao,Andrew Cherniack,Abner Louissaint,Valentina Nardi,Aaron R Thorner,Henry Long,Xintao Qiu,Elizabeth A Morgan,David M Dorfman,Danilo Fiore,Julie Jang,Alan L Epstein,Ahmet Dogan,Yanming Zhang,Steven M Horwitz,Eric D Jacobsen,Solimar Santiago,Jian-Guo Ren,Vincent Guerlavais,D Allen Annis,Manuel Aivado,Mansoor N Saleh,Amitkumar Mehta,Aviad Tsherniak,David Root,Francisca Vazquez,William C Hahn,Giorgio Inghirami,Jon C Aster,David M Weinstock,Raphael Koch
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com